MIRABEGRON AND UAS OUTCOMES DURING RIRS

Ankara Training and Research Hospital131 enrolled

Overview

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Study Type

OBSERVATIONAL

Enrollment

131

Conditions

Kidney Stone Retrograde Intrarenal Surgery (RIRS)Ureteral Access Sheath

Interventions

Retrograde intrarenal surgery

In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones. No additional intervention was performed beyond the routine surgical procedure.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients scheduled for RIRS due to kidney stones Exclusion Criteria: * preoperative ureteral stenting, * ureteral strictures, history of ureteral or bladder surgery, * anatomical abnormalities of the urinary tract, * active urinary tract infection, * pregnancy, * uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg), * use of medications affecting ureteral smooth muscle tone

Outcomes

Primary Outcomes

Ureteral access sheath insertion rate

Time frame: From January 2018 to October 2021

Secondary Outcomes

Ureteral injury rate

Time frame: From January 2018 to October 2024